Suven Pharmaceuticals Ltd
SUVENPHARSuven Pharmaceuticals Ltd
SUVENPHAR
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 127.02 | 14.89 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.22 | 6.55 | 0.48% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Suven Pharmaceuticals is engaged in Contract Research and Manufacturing Services (CRAMS), Drug Discovery & Development Support Services (DDDSS), Drug Discovery & Research/Clinical Pipeline, and Formulation Development
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 378.43 | 900.12 | 1,077.69 | 1,453.71 | 1,386.69 | 1,113.26 | 1,003.89 | |||||||
Raw Materials | 124.52 | 240.24 | 310.32 | 459.46 | 430.08 | 265.88 | 617.19 | |||||||
| Power & Fuel Cost | 18.06 | 38.24 | 44.20 | 59.55 | 73.93 | 48.30 | ||||||||
| Employee Cost | 29.63 | 65.10 | 76.23 | 100.48 | 118.25 | 135.92 | ||||||||
| Selling & Administrative Expenses | 16.23 | 44.76 | 44.96 | 53.18 | 46.45 | 41.00 | ||||||||
| Operating & Other expenses | 17.84 | 60.70 | 91.01 | 65.84 | 97.46 | 154.45 | ||||||||
EBITDA | 172.15 | 451.08 | 510.97 | 715.20 | 620.52 | 467.71 | 386.70 | |||||||
| Depreciation/Amortization | 11.50 | 23.51 | 31.64 | 39.10 | 47.99 | 54.60 | 55.33 | |||||||
| PBIT | 160.65 | 427.57 | 479.33 | 676.10 | 572.53 | 413.11 | 331.37 | |||||||
| Interest & Other Items | 2.79 | 23.07 | 11.67 | 8.53 | 12.81 | 7.45 | 6.55 | |||||||
| PBT | 157.86 | 404.50 | 467.66 | 667.57 | 559.72 | 405.66 | 324.82 | |||||||
| Taxes & Other Items | 48.59 | 87.51 | 105.34 | 213.78 | 148.44 | 105.39 | 84.35 | |||||||
| Net Income | 109.27 | 316.99 | 362.32 | 453.79 | 411.28 | 300.27 | 240.47 | |||||||
| EPS | — | 24.91 | 14.23 | 17.83 | 16.16 | 11.80 | 9.45 | |||||||
| DPS | 0.00 | 2.50 | 2.00 | 5.00 | 6.00 | 0.00 | 0.00 | |||||||
| Payout ratio | — | 0.10 | 0.14 | 0.28 | 0.37 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Suven Pharmaceuticals Ltd | 101.72 | 14.89 | — |
| Sun Pharmaceutical Industries Ltd | 47.86 | 6.83 | 0.71% |
| Cipla Ltd | 31.81 | 4.89 | 0.80% |
| Torrent Pharmaceuticals Ltd | 70.97 | 17.15 | 0.81% |
Price Comparison
Compare SUVENPHAR with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 9.90%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Suven Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
DSP ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9792% | Percentage of the fund’s portfolio invested in the stock 1.71% | Change in the portfolio weight of the stock over the last 3 months 0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/71 (+1) |
DSP Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9684% | Percentage of the fund’s portfolio invested in the stock 10.08% | Change in the portfolio weight of the stock over the last 3 months 0.70% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 2/33 (0) |
HSBC Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8825% | Percentage of the fund’s portfolio invested in the stock 1.56% | Change in the portfolio weight of the stock over the last 3 months 0.43% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/111 (+13) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateFeb 15, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Feb 15, 2022
Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live
Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chairman, effective 20 September 2024, as Vaidheesh Annaswamy decides to transition from the Board and becomes the Vice-Chair of Suven's Advisory council.Powered by Capital Market - Live
The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on record the following: Vaidheesh Annaswamy (DIN: 01444303) has decided to step down from his role as Executive Chairperson and Director of the Company, effective from close of business hours on 19 September 2024. Approved the appointment of Vivek Sharma (DIN: 08559495) as an Additional Director and Executive Chairman of the Company, as recommended by the Nomination and Remuneration Committee, for a period of five years with effect from 20 September 2024, subject to approval of the shareholders through postal ballot process. Powered by Capital Market - Live
Net profit of Suven Pharmaceuticals declined 49.61% to Rs 60.77 crore in the quarter ended June 2024 as against Rs 120.59 crore during the previous quarter ended June 2023. Sales declined 33.62% to Rs 230.69 crore in the quarter ended June 2024 as against Rs 347.55 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales230.69347.55 -34 OPM %34.6548.04 - PBDT96.49176.48 -45 PBT83.09163.94 -49 NP60.77120.59 -50 Powered by Capital Market - Live
Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
Technical Breakout Stocks: How to trade Torrent Power, Suven Pharma and Granules India on Thursday - Market Summary
Stock exchanges approve Cohance-Suven Pharma merger; NCLT application filed
L G Balakrishnan & Bros Ltd leads gainers in ‘A’ group
Suven Pharma Max Health can rally up to 9 Angel One
Suven Pharma soars after signing deal to acquire oligo drugs maker Sapala Organics
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 24.09%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.17% to 0.3%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 22.41%, vs industry avg of 15.28%